The DCM therapeutics market is anticipated to grow at a CAGR of 8.0% during the forecast period. In patients with DCM, the heart chambers become enlarged which in turn affects its ability to pump blood to the body. There are a number of factors that cause DCM such as genetic mutation, viral infections that affect the heart, exposure to toxins such as alcohol, and many more. In some cases, DCM also develops during the pregnancy or within three months from birth.

Various factors are promoting the DCM therapeutics market which include increasing the diagnosis rate of the DCM globally. Rising cases of drugs and alcohol abuse, increasing insurance coverage, and disposable income are also contributing to the market growth during the forecast period. Moreover, a number of companies are securing funding in the field of DCM therapeutics which is providing further opportunities to the market growth in the near future. However, the side effects of the drugs used for the treatment of DCM will restrict the growth of the market. Furthermore, the combination of conventional therapies with traditional medicines is presenting a new opportunity for the growth of the market during the forecast period.

Segmental Outlook 

The global DCM therapeutics market is segmented based on the drug class and therapy devices. Based on the drug class, the market is sub-segmented into angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, aldosterone antagonists, digitalis, angiotensin II receptor blockers, and anticoagulants. Further, based on the therapy devices, the market is sub-segmented into implantable cardioverter-defibrillators (ICDs), biventricular pacemakers, and heart pumps.

The biventricular pacemaker segment will be a considerable growing segment by the therapy device

The biventricular pacemaker segment is anticipated to grow with a significant CAGR in the DCM therapeutics market owing to its advantages when used in DCM patients. Biventricular pacemakers can acutely improve systolic function in patients with DCM. A biventricular pacemaker improves the survival, quality of life, and heart function of the DCM patients. Moreover, the use of biventricular pacemakers in DCM patients also decreases hospitalizations in select patients. Besides, this also aids in improving the symptoms and let the patients exercise freely. Hence, the aforementioned advantages are expected to significantly increase the market shares of the biventricular pacemaker segment in the DCM therapeutics market.

Global DCM therapeutics market Share by therapy devices, 2019 (%)

Regional Outlooks

The global DCM therapeutics market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to hold the largest market share in the DCM therapeutics market during the forecast period. The growth of the DCM therapeutics market in the region is owing to the presence of a technologically advanced healthcare system across the region. Additionally, the high incidence of DCM is also one of the major factors contributing to the high demand for drugs and devices related to DCM in the region. As per Renovacor Inc., DCM is affecting around 3 million people each year alone in the US. 

Global DCM therapeutics Market Growth, by Region 2020-2026

Asia-Pacific will augment with the fastest growth rate in the DCM therapeutics market 

Asia-Pacific is anticipated to witness the fastest growth rate in the DCM therapeutics market owing to the developing healthcare infrastructure in emerging economies including China, India, and ASEAN countries. Moreover, the high geriatric population base in Japan is also contributing to the market in the region. Additionally, changing lifestyle choices and increasing consumption of high calories diets also aids in cardiovascular disease. Moreover, the affordable healthcare system across the region is augmenting the medical tourism industry of the region and so DCM medical device market. 

Market Players Outlook

The key players of the DCM therapeutics market include Binance, Bitstamp Ltd., Blockstream Corp. Inc., BlockCypher, Inc., Coinbase UK, Ltd., Luno Pte. Ltd., BitMain Technologies Holding Co., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including merger & acquisition, collaborations with government, funding to the start-ups, and new product launches to stay competitive in the market. 

Recent Activities

• In October 2019, MyoKardia, Inc. announced the positive data from the company’s Phase 2a clinical trial of MYK-491. Additionally, the company also decided to advance to Phase 2 study of MYK-491 in patients with genetic DCM. MYK-491 is the company’s lead activator that is designed to increase the contractility of the heart with minimal or no effect on myocardial relaxation and compliance. MYK-491 is designed to act directly on the proteins in the heart muscle that are responsible for heart contraction.  
• In August 2019, Renovacor, Inc., secured Series A funding of $11 million which is intended to be used in the further development of its gene therapy-based treatments for DCM.
• In August 2018, Berlin Cures GmbH announced the successful completion of its Phase 1 study of BC 007, a DNA-based aptamer compound that is intended to be used for the treatment of DCM patients.

The Report Covers

• Market value data analysis of 2019 and forecast to 2026.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global DCM therapeutics market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.